OmniAb

OABIPre-clinical

OmniAb operates as a technology platform company, offering its partners a comprehensive suite of clinically proven antibody discovery technologies powered by proprietary transgenic animals. Its mission is to push the forefront of therapeutic antibody discovery by leveraging biological intelligence to generate optimized human antibody candidates. The company's strategic direction focuses on expanding its platform capabilities into novel modalities like peptides and single-domain antibodies, while deepening its computational and AI tools through OmniDeep™. With a strong leadership team and prestigious board, OmniAb is positioned as a key enabler in the global biopharma ecosystem.

Market Cap

$253.4M

Focus

Antibodies

OABI · Stock Price

USD 1.758.33 (-82.64%)

Historical price data

AI Company Overview

Technology Platform

OmniAb's core technology is its Biological Intelligence™ platform, comprising proprietary transgenic animals (OmniRat, OmniMouse, OmniChicken, OmniFlic, OmniClic, OmniTaur) and novel systems like OmniUltra for peptides/picobodies, all designed to generate and screen diverse, human-sequence antibody repertoires for therapeutic discovery.

Opportunities

Growth opportunities include expanding its partner base beyond the cited 100+ companies, leveraging novel platforms like OmniUltra for peptide and difficult target discovery, and deepening the integration of AI/ML tools (OmniDeep) to improve discovery efficiency.

The transition of partner programs into late-stage trials and commercialization represents a significant future royalty opportunity.

Risk Factors

Key risks include heavy reliance on the success and choices of third-party partners, intense competition in the antibody discovery platform sector, potential concentration of revenue from a few key partners, and the need for continuous high-level R&D investment to maintain technological leadership.

Competitive Landscape

OmniAb competes with antibody discovery service providers like AbCellera, BioNTech, and divisions of large CROs. Its main differentiation is its claim to offer the most comprehensive suite of transgenic animal platforms (multiple species), a focus on biological intelligence from in vivo systems, and extension into novel modalities like peptides and ultralong CDRH3 antibodies.